L'intérêt à découvert pour Travere Therapeutics donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Travere Therapeutics. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Travere Therapeutics (NASDAQ:TVTX) Stock, Rapport sur les intérêts à découvert

Travere Therapeutics

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics Inc

Reinsurance Group of America (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rga#NYSE">RGA</a>) shares have rallied 35.1% year to date (YTD) compared with the industry&#39;s growth of 21.5%. The Finance sector and the Zacks S&amp;P 500 index have returned 14.3% and 20% YTD, respectively. With a market capitalization of $14.39 billion, the average volume of shares traded in the last three months was 0.3 million.
<h2>RGA Outperforms Industry, Sector, S&amp;P YTD</h2>
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/01/79471.jpg?v=1113732845" />
Image Source: Zacks Investment Research
The rally was driven by its strong momentum in U.S. Traditional, Longevity/PRT, Asia Asset-Intensive and Asia Traditional, along with solid growth projections.
RGA has a VGM Score of A. VGM Score helps identify stocks with the most attractive value, best growth and the most promising momentum.
<h2>RGA Trading Above 50-Day and 200-Day Moving Average</h2>
This Zacks Rank #3 (Hold) insurance broker closed at $218.58 on Thursday, above its 50-day and 200-day simple moving average&nbsp;of $213.23 and $193.40, respectively, indicating solid upward momentum. SMA is a widely used technical analysis tool to predict future price trends by analyzing historical price data.
<h2>Reinsurance Group&#39;s Earnings Surprise History</h2>
Reinsurance Group has a decent earnings surprise history. Its earnings beat estimates in each of the last four quarters with an average surprise of 20.51%.
<h2>RGA&#39;s Growth Projection Encourages</h2>
The Zacks Consensus Estimate for Reinsurance Group&#39;s 2024 earnings per share indicates a year-over-year increase of 9.1%. The consensus estimate for revenues is pegged at $21.85 billion, implying a year-over-year improvement of 14.7%.
The consensus estimate for 2025 earnings per share indicates a year-over-year increase of 3.4% from the corresponding 2024 estimates.
The expected long-term earnings growth rate is 10.4%, outperforming the industry average of 4.6%. RGA has an impressive Growth Score of B. This style score helps analyze the growth prospects of a company.
<h2>Reinsurance Group&#39;s Return on Invested Capital</h2>
Its return on invested capital has increased every year. This reflects RGA&#39;s efficiency in utilizing funds to generate income. ROIC in the trailing 12 months was 6.8%, higher than the industry average of 0.6%.
<h2>Optimistic Analyst Sentiment for RGA</h2>
Each of the five analysts covering the stock has raised estimates for 2024, and four analysts have raised the same for 2025 over the past 60 days. The consensus estimate for 2024 and 2025 has moved 2.8% and 1.9% north, respectively, in the past 60 days.
<h2>RGA&#39;s Expensive Valuation</h2>
The stock is undervalued compared to its industry. It is currently trading at a price-to-book multiple of 1.46, lower than the industry average of 1.96.
<h2>Will RGA&#39;s Rally Stay?</h2>
Reinsurance Group is a leader in the U.S. and Latin American traditional markets. It has successfully expanded its product line with market-leading services, capabilities, expertise and innovation. Individual mortality has matured and provides a base for stable earnings and capital generation. 
Significant value embedded in the in-force business is anticipated to generate predictable long-term earnings. Product-line expansion contributes to risk diversification.
In Canada, Reinsurance Group is a market leader with solid growth and profitability. It has a sizable block of in-force business, which acts as a significant source of future earnings. Reinsurance Group expects longevity insurance, which is projected to witness steady demand, to experience long-term growth in the Canadian market. While longevity insurance provides a source of diversified income, it also acts as a hedge to a large mortality position.
Demand for protection products among the emerging global middle class and increasing demand for retirement, senior protection and savings products among aging populations create opportunities for growth in new business.
RGA is well-capitalized and has access to multiple forms of capital. RGA expects to remain active in deploying capital in attractive growth opportunities while balancing returning excess capital to shareholders over time.
RGA continues to ramp up technological inclusion with its product. This insurer is a global biometric liability reinsurance leader. Biometrics experience, which includes mortality, morbidity and longevity, over the last five quarters was favorable. Notably, its free cash flow conversion has remained more than 85% over the last many quarters, reflecting its solid earnings.
<h2>Wealth Distribution</h2>
This global reinsurer has also been managing capital effectively via share buybacks, dividend payments and prudent investments. RGA expects to remain active in deploying capital into attractive growth opportunities in organic flow and in-force block transactions and returning excess capital to shareholders through dividends and share repurchases. The company exited the second quarter of 2024 with excess capital of around $1 billion, reflecting a solid capital position.
<h2>Key Picks</h2>
Investors interested in the life insurance industry may look at some better-ranked players like Baldwin Insurance Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bwin#NASDAQ">BWIN</a>), Brighthouse Financial, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bhf#NASDAQ">BHF</a>) and Primerica, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pri#NYSE">PRI</a>), each carrying a Zacks Rank #2 (Buy) at present.
The Zacks Consensus Estimate for Baldwin Insurance&#39;s 2024 and 2025 earnings implies year-over-year growth of 38.3% and 32.2%, respectively. BWIN beat earnings estimates in each of the past four quarters, with an average surprise of 11.88%. Year to date, shares of BWIN have gained 108.4%.
The Zacks Consensus Estimate for Brighthouse Financial&#39;s 2024 and 2025 earnings implies year-over-year growth of 29.8% and 9.1%, respectively. It beat earnings estimates in three of the past four quarters while missing in one, with an average surprise of 3.76%. Year to date, shares of BHF have lost 16.3%.
The Zacks Consensus Estimate for Primerica&#39;s 2024 and 2025 earnings implies year-over-year growth of 12.2% and 10.9%, respectively. It beat earnings estimates in two of the past four quarters and missed in two, with an average surprise of 1.74%. Year to date, shares of PRI have climbed 29.6%.
<a href="https://www.zacks.com/stock/news/2342526/reinsurance-group-rallies-35-1-ytd-what-s-driving-the-stock?cid=CS-BENZ-FT-analyst_blog|price_surge_/_plunge-2342526">To read this article on Zacks.com click here.</a>

Earnings

Earnings Beats

Large Cap

Mid Cap

News

Dividends

Health Care

Small Cap

Markets

Analyst Ratings

Trading Ideas

Insurance

General

Brighthouse Financial, Inc. - Common Stock

BWIN

Reinsurance Group Rallies 35.1% YTD: What's Driving the Stock?

Wells Fargo analyst Roger Read maintains Exxon Mobil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) with a Overweight and raises the price target from $135 to $136.

Price Target

Wells Fargo Maintains Overweight on Exxon Mobil, Raises Price Target to $136

<a href="https://deadline.com/2024/09/scripps-news-layoffs-1236101676/" title="https://deadline.com/2024/09/scripps-news-layoffs-1236101676/">https://deadline.com/2024/09/scripps-news-layoffs-1236101676/</a>

'Scripps News To Cut More Than 200 Jobs, Scale Back National News Programming Amid "Difficult" Linear TV Advertising Market' -Deadline Report

Wells Fargo analyst Roger Read maintains Chevron (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) with a Overweight and lowers the price target from $196 to $169.

Wells Fargo Maintains Overweight on Chevron, Lowers Price Target to $169

AutoZone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>) has outperformed the market over the past 20 years by 12.03% on an annualized basis producing an average annual return of 20.45%. Currently, AutoZone has a market capitalization of $53.98 billion. 
Buying $100 In AZO: If an investor had bought $100 of AZO stock 20 years ago, it would be worth $4,139.84 today based on a price of $3189.33 for AZO at the time of writing.
<h3>AutoZone's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727451050_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In AutoZone 20 Years Ago Would Be Worth This Much Today

Booz Allen Hamilton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) has outperformed the market over the past 5 years by 3.74% on an annualized basis producing an average annual return of 18.08%. Currently, Booz Allen Hamilton has a market capitalization of $20.80 billion. 
Buying $100 In BAH: If an investor had bought $100 of BAH stock 5 years ago, it would be worth $226.69 today based on a price of $161.00 for BAH at the time of writing.
<h3>Booz Allen Hamilton's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727451044_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 5 Years Ago, You Would Have $200 Today

To gain an edge, this is what you need to know today.
<figure class="wp-block-image size-large is-resized"><img decoding="async" src="https://thearorareport.com/wp-content/uploads/2024/09/2024-09-27_08h59_50.png" alt="" style="width:624px" /></figure>
<h3 class="wp-block-heading">Spending Disappointment</h3>
Please <a href="https://thearorareport.com/chart-analysis-stock-market-spending-disappointment-boj-carry-trade-smci-mc-09272024">click here</a> for an enlarged chart of Super Micro Computer Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>).
Note the following:
<ul>
<li>This article is about the big picture, not an individual stock. The chart of SMCI stock is being used to illustrate the point.</li>
<li>A fortune is to be made in artificial intelligence, but it is not going to be in a straight line. At times, it is going to be treacherous.  It is important to not make mistakes by getting carried away with the momo crowd and listening to momo gurus who have a vested interest that is not your best interest.</li>
<li>The chart shows that momo crowd favorite SMCI fell yesterday on the news of a Department of Justice (DOJ) probe due to allegations of accounting irregularities. A DOJ probe is a serious matter as it is often a criminal probe.</li>
<li>The chart shows that the enthusiasm was at its peak right after SMCI stock was added to S&amp;P 500.</li>
<li>The chart shows from the peak to the low, the stock lost 69% of its value.</li>
<li>The chart shows that the day S&amp;P 500 added SMCI stock, The Arora Report made a bold call. The Arora Report call was that SMCI was worth only $442 &#8211; $486 in the best case. The stock peaked at $1229.  As of this writing in the premarket, SMCI stock is trading at $400.95.  All Arora Report calls are 100% transparent, traceable, and auditable. Members have access to over ten years of archives, including the winners and losers – no cherry picking.</li>
<li>Right now, the momo crowd is sitting on massive losses in SMCI stock. The momo crowd was not able to distinguish between NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Super Micro Computer – the prevailing belief among the momo crowd was that NVDA and SMCI were the same.</li>
<li>The U.S. economy is 70% consumer based. For this reason, prudent investors pay attention to personal income and personal spending.  Just released personal income and spending data is disappointing.  Here are the details of the new personal income and spending data:
<ul>
<li>Personal income came at 0.2% vs. 0.4% consensus.</li>
<li>Personal spending came at 0.2% vs. 0.3% consensus.</li>
</ul>
</li>
<li>PCE is the Fed&#8217;s favorite inflation gauge.&nbsp; Here are the details:
<ul>
<li>PCE came at 0.1% vs. 0.1% consensus.</li>
<li>Core PCE came at 0.1% vs. 0.2% consensus.</li>
<li>In The Arora Report analysis, the data is in line with expectations. As such, this data should have no impact on the stock market.</li>
<li>Even though the stock market pays a lot of attention to PCE, in The Arora Report analysis, economists have become really good at projecting PCE.&nbsp; As such, investors&#8217; expectations, in general, should be that PCE will come in line with consensus.</li>
</ul>
</li>
</ul>
<h3 class="wp-block-heading">Japan</h3>
Bank of Japan (BOJ) actions are very important for U.S. investors. The reason is the carry trade.  In carry trade, funds borrow in yen and invest in the U.S. stock market. Lately, they have been buying AI stocks. Japan's ruling party LDP has chosen Shigeru Ishiba as its new leader. Ishiba is the next prime minister of Japan. In The Arora Report analysis, yen is rallying on the news as Ishiba is a supporter of BOJ.
In The Arora Report analysis, this development is negative for the carry trade and positive for the yen position using ETF Invesco CurrencyShares Japanese Yen Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FXY#NYSE">FXY</a>) in The Arora Report&#8217;s ZYX Allocation.
<h3 class="wp-block-heading">Magnificent Seven Money Flows</h3>
In the early trade, money flows are positive in Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Alphabet Inc Class C (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>), Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), and Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>).
In the early trade, money flows are neutral in Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), and NVDA.
In the early trade, money flows are positive in SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>).
<h3 class="wp-block-heading">Momo Crowd And Smart Money In Stocks</h3>
Investors can gain an edge by knowing money flows in SPY and QQQ.  Investors can get a bigger edge by knowing when smart money is buying stocks, gold, and oil.  The most popular ETF for gold is SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>).  The most popular ETF for silver is iShares Silver Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLV#NYSE">SLV</a>).  The most popular ETF for oil is United States Oil ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>).
<h3 class="wp-block-heading">Bitcoin</h3>
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is on track to have the best September ever.
<h3 class="wp-block-heading">Protection Band And What To Do Now</h3>
It is important for investors to look ahead and not in the rearview mirror.
Consider continuing to hold good, very long term, existing positions. Based on individual risk preference, consider a protection band consisting of cash or Treasury bills or short-term tactical trades as well as short to medium term hedges and short term hedges. This is a good way to protect yourself and participate in the upside at the same time.
You can determine your protection bands by adding cash to hedges.&nbsp; The high band of the protection is appropriate for those who are older or conservative. The low band of the protection is appropriate for those who are younger or aggressive.&nbsp; If you do not hedge, the total cash level should be more than stated above but significantly less than cash plus hedges.
A protection band of 0% would be very bullish and would indicate full investment with 0% in cash.&nbsp; A protection band of 100% would be very bearish and would indicate a need for aggressive protection with cash and hedges or aggressive short selling.
It is worth reminding that you cannot take advantage of new upcoming opportunities if you are not holding enough cash.&nbsp; When adjusting hedge levels, consider adjusting partial stop quantities for stock positions (non ETF); consider using wider stops on remaining quantities and also allowing more room for high beta stocks.&nbsp; High beta stocks are the ones that move more than the market.
<h3 class="wp-block-heading">Traditional 60/40 Portfolio</h3>
Probability based risk reward adjusted for inflation does not favor long duration strategic bond allocation at this time.
Those who want to stick to traditional 60% allocation to stocks and 40% to bonds may consider focusing on only high quality bonds and bonds of five year duration or less.&nbsp; Those willing to bring sophistication to their investing may consider using bond ETFs as tactical positions and not strategic positions at this time.
The Arora Report is known for its accurate calls. The Arora Report correctly called the big artificial intelligence rally before anyone else, the new bull market of 2023, the bear market of 2022, new stock market highs right after the virus low in 2020, the virus drop in 2020, the DJIA rally to 30,000 when it was trading at 16,000, the start of a mega bull market in 2009, and the financial crash of 2008. Please click here to sign up for a free forever <a href="https://thearorareport.com/generate-wealth-newsletter-benzinga">Generate Wealth Newsletter</a>.

Market Summary

Economics

$BTC

AAPL

AMZN

GOOG

MSFT

NVDA

SMCI

TSLA

Personal Income And Spending Disappoint, Super Micro Computer Lesson, BOJ Supporter As Japan PM

WIIM

SMMT

Summit Therapeutics shares are trading lower after Citigroup downgraded the stock from Buy to Neutral but raised its price target from $19 to $23.

Goldman Sachs analyst Kate McShane maintains Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) with a Buy and raises the price target from $876 to $995.

COST

Goldman Sachs Maintains Buy on Costco Wholesale, Raises Price Target to $995

MP Materials shares are trading higher after Baird raised its price target on the stock from $20 to $25.

Wells Fargo analyst Roger Read maintains BP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>) with a Equal-Weight and lowers the price target from $39 to $35.

Wells Fargo Maintains Equal-Weight on BP, Lowers Price Target to $35

Legal

CHWY

SEC Says Former Chewy Executive Conducted Insider Trading In 2021

Melco Resorts & Entertainment Limited - American Depositary Shares

MLCO

Shares of Macau-linked casino and gaming stocks are trading higher possibly amid continued strength following a report suggesting China will issue up to $284 billion of sovereign debt as part of a stimulus.

Wells Fargo analyst George Kelly maintains Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) with a Equal-Weight and raises the price target from $800 to $850.

Wells Fargo Maintains Equal-Weight on Costco Wholesale, Raises Price Target to $850

Struggling chipmaker Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>)&nbsp;continues to receive <a target="_blank" href="https://www.benzinga.com/news/24/09/40968128/qualcomm-reportedly-eyes-potential-takeover-of-intel-amid-60-stock-decline-but-antitrust-concerns-lo" rel="noreferrer noopener">takeover proposals from</a> chip companies, the latest being Arm Holdings Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) following Qualcomm Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) proposal earlier.
Arm Holdings recently proposed to acquire Intel&#8217;s product unit. However, Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2024-09-27/arm-rejected-by-intel-after-approaching-it-about-buying-product-unit?sref=TBDibEcD" rel="noreferrer noopener">reports</a> that Intel is not looking to sell the business division.
Intel stock plunged 31% as it failed to capitalize on the artificial intelligence shift, which is something that contract chipmaker Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) excelled at.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/09/41012678/super-micro-unveils-next-gen-servers-powered-by-intels-latest-xeon-chips" rel="noreferrer noopener">Super Micro Unveils Next-Gen Servers Powered by Intel&#8217;s Latest Xeon Chips</a>
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="750" height="650" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/27091711/newplot-1-7.png" alt="" class="wp-image-569782" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/27091711/newplot-1-7.png 750w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/27091711/newplot-1-7-300x260.png 300w" sizes="(max-width: 750px) 100vw, 750px" /></figure>
Meanwhile, some reports indicated Intel&#8217;s plans to convert its <a target="_blank" href="https://www.benzinga.com/news/24/09/40897994/whats-going-on-with-intel-stock-on-tuesday" rel="noreferrer noopener">foundry business into</a> an independent unit, including exploring a spinoff into a publicly traded company. The chipmaker also explored divesting stake in the programmable chip unit&nbsp;Altera.
However, Intel&#8217;s recent big wins included a&nbsp;U.S. chipmaking deal from&nbsp;Amazon.Com Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) Amazon Web services and the U.S. Chip grant.
The chipmaker also clarified that it would not divest a majority stake in the struggling <a target="_blank" href="https://www.benzinga.com/news/24/09/40941075/whats-going-on-with-autonomous-driving-stock-mobileye-thursday" rel="noreferrer noopener">Israeli autonomous driving company</a> Mobileye Global Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>), whose stock is down 66% in the last 12 months.
Intel&#8217;s exploration of stake sales to companies like Qualcomm and Arm could hinder its U.S. subsidy over antitrust grounds, the Financial Times <a target="_blank" href="https://www.ft.com/content/ff0ca77d-ad35-45ba-a493-201a26932efb" rel="noreferrer noopener">reports</a>.
Multiple deals including Nvidia&#8217;s proposal to snap Arm Holdings from&nbsp;Softbank Group Corp (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBF#OTC">SFTBF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBY#OTC">SFTBY</a>) and Intel&#8217;s&nbsp;Tower Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSEM#NASDAQ">TSEM</a>) deal have succumbed to global regulatory opposition.
The semiconductor sector had a good week, buoyed by the <a target="_blank" href="https://www.benzinga.com/news/earnings/24/09/41046485/whats-going-on-with-nvidia-braodcom-intel-and-other-chip-stocks-on-thursday" rel="noreferrer noopener">key rate cuts</a> in the U.S. and China, an upbeat quarterly print from Micron Technology, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>), and continued AI investments from Big Tech companies.
Semiconductor ETFs, Invesco Semiconductors ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSI#NYSE">PSI</a>) and SPDR S&amp;P Semiconductor ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XSD#NYSE">XSD</a>), gained 5%- 7% in the last five days.
Price Action: INTC stock is down 0.04% at $23.91 at the last check on Friday.
Photo via Shutterstock

Tech

Media

INTC

MBLY

PowerShares Exchange-Traded Fund Trust Dynamic Semiconductor Portfolio

QCOM

SFTBF

SFTBY

TSEM

What's Going On With Intel Stock On Friday?

Politics

Multiple Blasts Heard In Beirut, According To Reuters Witness, 'Massive Thick Clouds Of Smoke' Rising From City

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) with a Buy and maintains $10 price target.

Reiteration

LXRX

HC Wainwright & Co. Reiterates Buy on Lexicon Pharmaceuticals, Maintains $10 Price Target

On CNBC: Tanger Outlet CEO Discusses Shopping Trends, Consumer Demand

GDRX

PETS

Shares of pharmacy stocks are trading higher. Costco on its earnings call said pharmacy had the strongest sales percentage increase within ancillary businesses, with a double-digit script count growth, which could possibly be lifting the sector.

High-rolling investors have positioned themselves bullish on McDonald's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in MCD often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 8 options trades for McDonald's. This is not a typical pattern.
The sentiment among these major traders is split, with 50% bullish and 12% bearish. Among all the options we identified, there was one put, amounting to $107,640, and 7 calls, totaling $441,864.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $145.0 and $440.0 for McDonald's, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in McDonald's's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to McDonald's's substantial trades, within a strike price spectrum from $145.0 to $440.0 over the preceding 30 days.
<h3>McDonald's Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727450251_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCD</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$163.9</td>
<td>$161.1</td>
<td>$162.7</td>
<td>$145.00</td>
<td>$113.8K</td>
<td>1</td>
<td>7</td>
</tr>
<tr>
<td>MCD</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$136.9</td>
<td>$132.5</td>
<td>$134.55</td>
<td>$440.00</td>
<td>$107.6K</td>
<td>0</td>
<td>8</td>
</tr>
<tr>
<td>MCD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/04/24</td>
<td>$2.9</td>
<td>$2.72</td>
<td>$2.9</td>
<td>$305.00</td>
<td>$66.7K</td>
<td>2.4K</td>
<td>355</td>
</tr>
<tr>
<td>MCD</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>10/04/24</td>
<td>$3.6</td>
<td>$3.45</td>
<td>$3.53</td>
<td>$305.00</td>
<td>$66.3K</td>
<td>2.4K</td>
<td>1.1K</td>
</tr>
<tr>
<td>MCD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/04/24</td>
<td>$3.1</td>
<td>$2.96</td>
<td>$3.1</td>
<td>$305.00</td>
<td>$62.0K</td>
<td>2.4K</td>
<td>642</td>
</tr>
</tbody>
</table>

<h3>About McDonald's</h3>
McDonald's is the largest restaurant owner-operator in the world, with 2023 system sales of $130 billion across nearly than 42,000 stores and 115 markets. McDonald's pioneered the franchise model, building its footprint through partnerships with independent restaurant franchisees and master franchise partners around the globe. The firm earns roughly 60% of its revenue from franchise royalty fees and lease payments, with most of the remainder coming from company-operated stores across its three core segments: the United States, internationally operated markets, and international developmental/licensed markets.
Following our analysis of the options activities associated with McDonald's, we pivot to a closer look at the company's own performance.
<h3>Current Position of McDonald's</h3>
<ul>
<li>With a volume of 533,349, the price of MCD is up 0.94% at $306.51. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 31 days.</li>
</ul>
<h3>What Analysts Are Saying About McDonald's</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $303.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Goldman Sachs persists with their Neutral rating on McDonald's, maintaining a target price of $325. 
&#x2A; An analyst from TD Cowen has revised its rating downward to Hold, adjusting the price target to $280. 
&#x2A; An analyst from Citigroup persists with their Neutral rating on McDonald's, maintaining a target price of $301. 
&#x2A; Maintaining their stance, an analyst from Baird continues to hold a Outperform rating for McDonald's, targeting a price of $320. 
&#x2A; An analyst from JP Morgan has decided to maintain their Overweight rating on McDonald's, which currently sits at a price target of $290. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for McDonald's, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

This Is What Whales Are Betting On McDonald's

Travere Therapeutics (TVTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yigal Nochomovi...

Upgraded Buy Rating and Target Price for Travere Therapeutics on Filspari's Market Expansion and Approval

In a report released on September 5, Joseph Schwartz from Leerink Partners reiterated a Buy rating on Travere Therapeutics (TVTX – Research Report)...

Buy Rating Affirmed for Travere Therapeutics Following Filspari's Expanded FDA Approval and Positive Market Outlook

Wells Fargo analyst Mohit Bansal maintained a Hold rating on Travere Therapeutics (TVTX – Research Report) on September 6. The company's shares clo...

Travere Therapeutics (TVTX) Gets a Hold from Wells Fargo

Travere Therapeutics (TVTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ed Arce from H....

Buy Rating Affirmed for Travere Therapeutics Amid Proactive HARMONY Study Management and Strong Financial Stance

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Entera Bio (ENTX – Research Report), Legend Biotech ...

Analysts Are Bullish on These Healthcare Stocks: Entera Bio (ENTX), Legend Biotech (LEGN)

Travere slips after pausing late-stage trial's enrollments

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Travere Therapeutics (TVTX – Research Report) today and set a price target of $15.00. T...

TD Cowen Sticks to Its Buy Rating for Travere Therapeutics (TVTX)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Adverum Biotechnologies (ADVM – Research Report), Bi...

Analysts Offer Insights on Healthcare Companies: Adverum Biotechnologies (ADVM), Biomea Fusion (BMEA) and Travere Therapeutics (TVTX)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on DENTSPLY SIRONA (XRAY – Research Report) and Travere...

Analysts Offer Insights on Healthcare Companies: DENTSPLY SIRONA (XRAY) and Travere Therapeutics (TVTX)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Curis (CRIS – Research Report), Scholar Rock Holding...

Analysts Offer Insights on Healthcare Companies: Curis (CRIS), Scholar Rock Holding (SRRK) and Travere Therapeutics (TVTX)

ADVM

BMEA

CRIS

ENTX

LEGN

SRRK

TVTX

XRAY

Press Releases

Travere Therapeutics to Report Second Quarter 2024 Financial Results

Travere Therapeutics Reports Second Quarter 2024 Financial Results

Ligand Reports Second Quarter 2024 Financial Results

Travere Therapeutics to Present at Upcoming Investor Conferences

Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024

Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up

Comments

Travere Therapeutics

Intérêt court

Travere Therapeutics (NASDAQ:TVTX) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL